For the quarter ended March, the company posted 5% higher net profit at ₹406 crore (₹386.3 crore) on a nearly 16% increase to ₹1,287.3 crore (₹1,110.3 crore).
Natco Pharma estimates a possible dip in revenue by 20% and profit by as much 30% in FY26 due to geopolitical uncertainties and pricing pressure in its core product portfolio in the U.S. and on account of increased research and development (R&D) expenses.
On the back of a strong cash position of over ₹3,000 crore as of March 31, 2025, it is preparing for headwinds coming from its U.S. business during the current fiscal. The Hyderabad-based generic drugmaker said this announcing consolidated net profit for 2024-25 at ₹1,883.4 crore and total revenue of ₹4,784 crore were the highest thus far.
The financial performance last fiscal was “result of decades of our diligence,” Natco Pharma. While net profit was an increase of 36% compared to ₹1,388.3 crore in 2023-24, total revenue was 16% higher from ₹4,126.9 crore year earlier.
https://www.thehindu.com/business/front-end-manufacturing-in-us-way-forward-to-counter-tariff-impact-on-pharma-natco-pharma-ceo/article69243853.ece
The guidance for the current fiscal comes after vice-chairman and CEO Rajeev Nannapaneni in February this year told investors, in the backdrop of U.S. threatening high tariffs on pharma imports, about the need for a front-end manufacturing in the U.S. That’s the only way you can go forward. Appears to be the only solution, he had said.
For the quarter ended March, the company posted 5% higher net profit at ₹406 crore (₹386.3 crore) on a nearly 16% increase to ₹1,287.3 crore (₹1,110.3 crore).
During the quarter, the company took an impairment charge of ₹50 crore in the Crop Health Science business related to property, plant and machinery, a chargeback adjustment of approximately ₹25 crore in its U.S. subsidiary apart from higher R&D expenses.
Published – May 28, 2025 08:08 pm IST
